Survival Advantage Demonstrated With Higher-Dose Rhenium-186 Nanoliposome in Recurrent Glioma (Cancer Network) - Sep 9, 2022 - P1/2 | N=55 | ReSPECT (NCT01906385) | Sponsor: Plus Therapeutics | "Data from the phase 1 ReSPECT-GBM trial (NCT01906385) showed promising safety and efficacy results with use of Rhenium-186 nanoliposome (186RNL) administered at doses exceeding 100 Gy in patients with recurrent glioma. Lead author Andrew J. Brenner, MD, PhD...presented findings at the 2022 European Society for Medical Oncology Congress showing that 186RNL extended overall survival (OS) when patients receive at least 100 Gy radiation. The median OS was 22.9 months (95% CI, 8.8-42.3) for those who received at least 100 Gy of 186RNL compared with just 5.6 months (95% CI, 1.6-9.4) for those who received a smaller dose. Median OS for the entire cohort (N = 23) was 9.4 months (95% CI, 5.8-13.2). Three patients in the 100 Gy or higher group remain alive compared with no patients in the lower group."
P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|